We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for streaming realtime charts, analysis tools, and prices.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bristol Myers Squibb Co | NYSE:BMY | NYSE | Common Stock |
| Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|
| -0.51 | -1.15% | 43.70 | 44.42 | 43.333 | 44.38 | 15,927,299 | 21:56:22 |
From May 2019 to May 2024
By Tess Stynes
Bristol-Myers Squibb Co. (BMY) expanded its collaboration effort with CytomX Therapeutics Inc. (CTMX) to a third experimental cancer treatment target, triggering a $10 million milestone payment for the California biopharmaceutical company.
CytomX uses its Probody drug-development platform to develop immunotherapy treatments and to improve the tumor-targeting capabilities and safety of cancer therapies.
Under the May 2014 collaboration deal, Bristol-Myers received exclusive global rights to develop and commercialize Probodies for as many as four cancer targets.
CytomX received an upfront payment of $50 million and is eligible for selection payments when Bristol-Myers selects the third and fourth targets. CytomX also is eligible to receive additional payments including as much as $298 million in future milestone payments for each collaboration target.
Write to Tess Stynes at tess.stynes@wsj.com
(END) Dow Jones Newswires
January 20, 2016 09:03 ET (14:03 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Bristol Myers Squibb Chart |
1 Month Bristol Myers Squibb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
